Silas Inman

Intravitreal aflibercept injection showed a high level of ≥2-step improvement in DRSS compared with sham for patients with moderately severe to severe nonproliferative diabetic retinopathy.

Treatment with subretinal transplantation of allogeneic human retinal progenitor cells showed promising early signs of efficacy as a treatment for individuals with retinitis pigmentosa.

AAV2/5-OPTIRPE65 showed improvements in vision-guided mobility, retinal sensitivity, and foveal-driven visual function for patients with RPE65-associated retinal dystrophy.

MET inhibitor capmatinib may hold promise for a small subtype of patients with a non-small cell lung cancer, according to new ASCO 2019 findings.

The FDA has approved the first-in-class CGRP monoclonal antibody erenumab for the prevention of migraines in adults, based on findings from three clinical trials.

Intravitreal aflibercept injection showed early signs of activity for patients with moderately severe to severe nonproliferative diabetic retinopathy.

The novel immune-based treatment IMCgp100 demonstrated a 1-year survival rate of 73% for patients with heavily pretreated, advanced uveal melanoma.

Voretigene neparvovec demonstrated sustained improvements in vision for patients with biallelic RPE65-mutation–associated inherited retinal disease.

Outcomes for patients with nAMD in the real-world were inferior to randomized controlled trials due to significant undertreatment.

An automated artificial intelligence-based system was approximately 70% accurate at predicting optimal retreatment intervals for nAMD.

Brolucizumab, which could be given every 12 weeks, showed non-inferior improvements in BCVA when compared with aflibercept every 8 weeks.

Use of a 0.18 mg fluocinolone acetonide intravitreal insert effectively lowered the rate of uveitis recurrences and cumulative total recurrent episodes.

A fully automated artificial intelligence-based system could effectively classify function and potency of cell therapy.

A wave of novel gene therapies is on the horizon as treatments for patients with retinitis pigmentosa.

Alemtuzumab showed significant reductions in MRI lesions and slowed brain volume loss in 5-year results for RRMS.

ICON-1 plus ranibizumab effectively reduced CNV size and led to complete drying of the retina for some patients with wet AMD.

Intravitreal bevacizumab effectively lowered the risk of retinal detachment recurrence after primary pars plana vitrectomy.

The FDA has approved guselkumab for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

The Synthroid brand of levothyroxine improved thyroid-stimulating hormone (TSH) levels by a significantly greater margin compared with generic versions of the synthetic T4 (LT4) hormones for patients with hypothyroidism.

The expanded indication was granted under the FDA's priority review program.

The FDA has issued a complete response letter for the oral and intravenous antibiotic solithromycin as a treatment for patients with community-acquired bacterial pneumonia, due to concerns over hepatotoxicity and manufacturing issues.